IAA7 Antibody

What is IAA7 and why are antibodies against it important in plant science?

IAA7 (also known as AXR2) is an auxin-responsive protein that functions as a transcriptional repressor in early auxin response pathways in plants. IAA7 belongs to the Aux/IAA family of proteins that are short-lived transcription factors mediating auxin-regulated gene expression . These proteins repress early auxin response genes at low auxin concentrations through interaction with auxin response factors (ARFs) that bind to auxin-responsive promoter elements (AuxRE) .

Antibodies against IAA7 are critically important because they enable researchers to:

• Track IAA7 protein levels during auxin signaling events

• Study protein-protein interactions involving IAA7

• Investigate the degradation kinetics of IAA7 in response to auxin

• Validate gene expression and protein localization in transgenic plant lines

The miniIAA7 (mIAA7) degron sequence in particular has become important in developing protein degradation technologies, making antibodies against this sequence valuable research tools .

How does the structure of IAA7 relate to its functional properties?

IAA7 contains distinct structural domains with specific functions in auxin signaling:

Interestingly, disorder prediction algorithms consistently show that most of the disordered segments in IAA7 are located in the N-terminal domain, with an enrichment of hydrophilic residues indicating these regions are likely solvent-exposed . The intrinsic disorder of these regions is believed to be critical for the protein's function in auxin sensing and rapid degradation.

What distinguishes the miniIAA7 degron from the full-length IAA7 protein?

The miniIAA7 (mIAA7) degron represents a minimized version of the degron sequence found in full-length IAA7. It contains the core sequence necessary for auxin-dependent interaction with TIR1/AFB F-box proteins and subsequent ubiquitination .

Key differences include:

• Size: mIAA7 is significantly shorter than full-length IAA7, containing only the essential degron elements

• Function: mIAA7 shows less basal degradation compared to full-length AID tags, making it useful for applications requiring tight control of degradation

• Efficiency: While mIAA7 shows reduced basal degradation, it works less efficiently than full-length mAID tags when degradation is induced

• Lysine content: mIAA7 has fewer lysine residues for ubiquitylation compared to full-length IAA7

These properties make anti-miniIAA7 antibodies particularly valuable for detecting fusion proteins in degron-based protein degradation systems.

How are IAA7 antibodies used in the auxin-inducible degron (AID) technology?

IAA7 antibodies serve multiple critical functions in auxin-inducible degron (AID) technology:

• Validation of tagged proteins: Researchers use anti-IAA7 antibodies to confirm successful tagging of target proteins with IAA7-derived degrons through Western blotting

• Degradation kinetics monitoring: These antibodies enable precise tracking of protein depletion rates after auxin addition

• System optimization verification: When developing improved AID systems (like AID2), anti-IAA7 antibodies help compare degradation efficiency between different system variants

• Background degradation assessment: A key challenge in AID technology has been leaky degradation in the absence of auxin. IAA7 antibodies allow researchers to quantify this background degradation, which is essential when evaluating modified systems like the AID2 system that employs OsTIR1(F74G) and 5-Ph-IAA

• Cross-system comparison: Anti-IAA7 antibodies facilitate comparison between different degron systems, such as comparing miniIAA7 (mIAA7) tagged proteins with standard mAID tagged proteins

The development of AID2 system has significantly improved protein degradation control, showing no detectable leaky degradation, requiring 670-times lower ligand concentration, and achieving quicker degradation than conventional AID . IAA7 antibodies played a crucial role in validating these improvements.

What methodological approaches optimize IAA7 antibody usage in protein degradation studies?

When utilizing IAA7 antibodies for protein degradation research, several methodological considerations can enhance experimental outcomes:

• Optimal fixation protocol:

  • For immunofluorescence applications, 4% paraformaldehyde fixation for 15-20 minutes generally preserves IAA7 epitopes while maintaining cellular architecture

  • Avoid methanol fixation as it may disrupt the conformation of intrinsically disordered regions in IAA7

• Blocking strategy:

  • Use 5% BSA in TBST for blocking to minimize background

  • Include 0.1% Triton X-100 for permeabilization when conducting immunofluorescence

• Antibody dilution optimization:

  • Typical starting dilutions: 1:500-1:1000 for Western blot; 1:100-1:200 for immunofluorescence

  • Always perform titration experiments to determine optimal concentration for specific applications

• Controls for degradation experiments:

  • Include OsTIR1(F74G) expressing cells without auxin analog addition

  • Use auxin-insensitive mutant controls (e.g., IAA7 with P87S mutation) to verify specificity

  • Compare degradation kinetics between different degron systems (mIAA7 vs. mAID)

• Quantification approach:

  • Use fluorescence intensity measurements from multiple cells/fields

  • Normalize to total protein loading or housekeeping proteins

  • Apply time-course analysis to accurately determine degradation kinetics and half-life

Researchers have found that the combination of OsTIR1(F74G) with standard mAID tags provides more efficient degradation than OsTIR1 with the miniIAA7 tag, highlighting the importance of system optimization and validation using anti-IAA7 antibodies .

How can IAA7 antibodies facilitate investigation of intrinsically disordered regions in plant proteins?

IAA7 antibodies provide valuable tools for studying intrinsically disordered regions (IDRs) in plant signaling proteins:

• Epitope accessibility analysis:

  • IAA7 contains substantial IDRs, particularly in its N-terminal domain (NTD)

  • Antibodies targeting different epitopes within these regions can help map their accessibility and solvent exposure under various conditions

  • Changes in epitope recognition can reveal conformational shifts in these disordered regions during protein-protein interactions

• Structure-function relationship studies:

  • By comparing antibody binding to wild-type IAA7 versus mutant variants, researchers can identify how specific residues contribute to IDR dynamics

  • For example, mutation P87S in IAA7 (axr2-1) abolishes interaction with TIR1, which can be monitored using anti-IAA7 antibodies

• Partner-induced folding detection:

  • IDRs often undergo folding upon binding to interaction partners

  • Differential antibody accessibility before and after interaction with TIR1 or ARFs can reveal such structural transitions

• IDR conservation assessment:

  • Comparing epitope recognition across different Aux/IAA family members can reveal conserved structural features within disordered regions

  • This approach helps distinguish functionally important disorder from sequence variability

The strategic use of antibodies targeting different regions of IAA7 has revealed that almost 50% of IAA7's amino acid content corresponds to disordered regions, with a notable "order-dip" corresponding to the core degron sequence . This structural arrangement appears critical for the protein's function in auxin sensing.

What factors affect IAA7 antibody specificity and how can cross-reactivity be minimized?

Several factors influence IAA7 antibody specificity, with corresponding strategies to minimize cross-reactivity:

When validating anti-IAA7 antibody specificity:

• Include genetic knockouts or knockdowns as negative controls

• Perform peptide competition assays to confirm epitope specificity

• Compare results using antibodies targeting different IAA7 epitopes

• Validate using orthogonal methods (e.g., MS-based proteomics, GFP-fusion proteins)

• Test reactivity against recombinant IAA7 and related proteins (e.g., IAA12)

How can researchers optimize detection of IAA7-tagged proteins in different experimental systems?

Optimizing detection of IAA7-tagged proteins requires system-specific approaches:

• Cell culture systems:

  • Harvest cells at optimal timepoints based on degradation kinetics (typically 0.5-2 hours after auxin addition)

  • Use gentle lysis buffers containing phosphatase inhibitors to preserve protein modifications

  • Consider subcellular fractionation to enrich for nuclear fraction where many IAA7-interacting proteins localize

• Plant tissue samples:

  • Optimize extraction buffers to account for plant-specific compounds that may interfere with antibody binding

  • Consider tissue-specific expression patterns when selecting samples

  • Use high-sensitivity detection methods for tissues with low expression

• Yeast two-hybrid systems:

  • When analyzing IAA7 interactions using Y2H as in chimeric IAA7/IAA12 studies, antibody detection can verify expression levels of bait and prey constructs

  • Apply stringent washing protocols to reduce background in co-immunoprecipitation experiments

• Detection method optimization:

  • For Western blotting: Consider using PVDF membranes instead of nitrocellulose for higher protein retention

  • For immunofluorescence: Use high-NA objectives and deconvolution microscopy to improve signal detection

  • For flow cytometry: Optimize permeabilization conditions to maintain cellular integrity while allowing antibody access

• Signal amplification approaches:

  • Tyramide signal amplification for immunohistochemistry

  • Enhanced chemiluminescence with longer exposure times for Western blots

  • Consider proximity ligation assays for detecting IAA7 interactions in situ

These optimization strategies have proven particularly important when working with modified degron systems like miniIAA7 (mIAA7), which shows less basal degradation but also reduced degradation efficiency compared to standard mAID tags .

What are the critical considerations when using IAA7 antibodies in different experimental techniques?

Each experimental application of IAA7 antibodies requires specific technical considerations:

• Western Blotting:

  • Sample preparation: IAA7 is prone to rapid degradation; use fresh samples with protease inhibitors

  • Gel percentage: Use 10-12% gels for full-length IAA7 (~35 kDa) and 15% gels for miniIAA7 fragments

  • Transfer conditions: Semi-dry transfer at 15V for 30 minutes typically works well for IAA7

  • Blocking: 5% non-fat dry milk in TBST often provides optimal signal-to-noise ratio

  • Detection: IAA7 degradation studies often require quantitative analysis; consider fluorescent secondary antibodies for linear quantification

• Immunoprecipitation:

  • Pre-clearing: Essential to reduce non-specific binding

  • Antibody coupling: Consider covalent coupling to beads to avoid heavy chain interference in subsequent analysis

  • Washing stringency: Balance between maintaining specific interactions and reducing background

  • Elution conditions: Gentle elution with peptide competition may preserve interacting partners

• Immunofluorescence:

  • Fixation: 4% PFA preserves IAA7 epitopes while maintaining cellular architecture

  • Antigen retrieval: May be necessary for some fixed tissues

  • Controls: Include peptide competition and secondary-only controls

  • Co-localization studies: Consider spectral unmixing for multi-color applications

• Chromatin Immunoprecipitation (ChIP):

  • Crosslinking: Optimize formaldehyde concentration and time

  • Sonication: Adjust conditions to generate 200-500 bp fragments

  • IP conditions: More stringent washing than standard IP

  • Controls: Include IgG control and input normalization

• Flow Cytometry:

  • Cell preparation: Gentle fixation and permeabilization to maintain epitope accessibility

  • Antibody titration: Critical to determine optimal concentration

  • Compensation: Essential for multi-color applications

  • Gating strategy: Include appropriate negative controls

When designing experiments using IAA7 antibodies, researchers should consider the rapid degradation kinetics of IAA7 proteins, which can be fully depleted within 30 minutes in optimized AID2 systems . This rapid turnover necessitates careful timing of sample collection and processing.

How can IAA7 antibodies contribute to studying structure-function relationships in auxin signaling?

IAA7 antibodies enable sophisticated approaches to investigate structure-function relationships in auxin signaling:

• Domain swap experiments:

  • Researchers have created chimeric proteins by exchanging modules between IAA7 and IAA12, including the domain I (DI), degron, linker, degron tail, and PB1 domain

  • Anti-IAA7 antibodies can track the expression and stability of these chimeras to determine how specific domains contribute to function

  • For example, Y2H studies revealed that native IAA7 (designated 7-7-7-7-7) interacts with TIR1 in an auxin-dependent manner more strongly than native IAA12 (12-12-12-12-12)

• Mutation analysis:

  • Point mutations in the IAA7 degron, such as P87S in the iaa7/axr2-1 mutant, abolish association with TIR1

  • Anti-IAA7 antibodies can detect these mutant proteins and assess how mutations affect stability and interactions

• Binding kinetics studies:

  • Antibodies enable measurement of auxin binding affinities in TIR1·IAA7 complexes

  • Research shows that PB1-compromised IAA7 (IAA7 BM3) with TIR1 shows diminished auxin binding affinity (Kd = ~53 ± 2 nM) compared to wild-type IAA7 with TIR1 (Kd = ~20 ± 3 nM)

• Conformational dynamics analysis:

  • Using epitope-specific antibodies to probe changes in IAA7 structure upon interaction with TIR1 or ARFs

  • This approach has revealed how intrinsically disordered regions in IAA7 contribute to protein function

These approaches have demonstrated that the TIR1·IAA(7-7-7-7-7) complex has significantly higher auxin binding affinity compared to chimeric complexes where domains have been swapped with IAA12, highlighting the importance of domain-specific contributions to auxin sensing .

What emerging technologies can be combined with IAA7 antibodies to advance plant science research?

Integration of IAA7 antibodies with cutting-edge technologies opens new research avenues:

• Advanced microscopy techniques:

  • Super-resolution microscopy (SIM, STORM, PALM) with IAA7 antibodies enables visualization of protein distributions below the diffraction limit

  • Single-molecule tracking can follow IAA7 dynamics in living cells when combined with minimally invasive labeling approaches

  • Light-sheet microscopy allows visualization of IAA7 degradation in intact plant tissues with minimal photodamage

• Proximity labeling technologies:

  • BioID or TurboID fused to IAA7 can identify proximal proteins in the auxin signaling complex

  • APEX2-based approaches provide temporal resolution to capture dynamic interaction networks

  • Antibodies validate these approaches and help calibrate labeling efficiency

• Active learning approaches for antibody-antigen interaction prediction:

  • Machine learning models can predict antibody-antigen binding, especially valuable when designing new IAA7 antibody variants

  • Active learning strategies reduce experimental costs by starting with a small labeled subset and iteratively expanding the labeled dataset

  • Some algorithms have reduced the number of required antigen mutant variants by up to 35% compared to random testing approaches

• Mass spectrometry integration:

  • Immunoprecipitation with IAA7 antibodies followed by mass spectrometry identifies interaction partners and post-translational modifications

  • SILAC or TMT labeling enables quantitative analysis of IAA7 degradation kinetics

  • Crosslinking mass spectrometry (XL-MS) maps interaction interfaces between IAA7 and binding partners

• Genomic engineering coupled with antibody detection:

  • CRISPR/Cas9-mediated tagging of endogenous IAA7 with minimal epitope tags

  • Antibodies against these tags enable tracking of native IAA7 dynamics

  • The AID2 system with OsTIR1(F74G) and 5-Ph-IAA provides precise control over IAA7-tagged protein degradation in diverse organisms

These integrated approaches have demonstrated that AID2 technology achieves rapid target depletion not only in yeast and mammalian cells but also in mice, opening new possibilities for studying auxin-related mechanisms across systems .

How do variations in IAA7 structure across plant species impact antibody selection and experimental design?

Evolutionary conservation patterns in IAA7 have significant implications for antibody applications:

• Epitope conservation analysis:

  • While the core degron sequence of IAA7 is conserved across plant species, flanking regions show greater variability

  • Researchers should select antibodies targeting either highly conserved regions (for cross-species applications) or variable regions (for species-specific detection)

  • Sequence alignment analysis prior to antibody selection can predict cross-reactivity across species

• Species-specific considerations:

  • IAA7 orthologs in different plant species may exhibit different:
    a) Expression levels requiring adjusted antibody concentrations
    b) Post-translational modification patterns affecting epitope accessibility
    c) Interaction dynamics with TIR1/AFB proteins

  • Validation experiments should be performed in each species of interest

• Applications in comparative plant biology:

  • Anti-IAA7 antibodies enable comparison of auxin signaling mechanisms across evolutionary distant plant species

  • When designing experiments across species, consider:
    a) Optimizing extraction buffers for species-specific tissues
    b) Adjusting incubation conditions based on species-specific protein characteristics
    c) Including appropriate controls for each species

• Engineered systems across species boundaries:

  • The AID2 system utilizing OsTIR1(F74G) from rice with the synthetic auxin analog 5-Ph-IAA works efficiently across yeast, mammalian cells, and mice

  • IAA7 antibodies can validate these heterologous systems and quantify degradation efficiency

Understanding these evolutionary considerations has facilitated the application of auxin-inducible degron technologies across diverse experimental systems, from plants to animals, expanding the utility of IAA7-based approaches in broader biological research .

What innovations in IAA7 antibody development could address current limitations?

Several promising innovations could overcome current limitations in IAA7 antibody applications:

• Conformation-specific antibodies:

  • Development of antibodies that specifically recognize IAA7 in either its free state or TIR1-bound conformation

  • These would enable direct monitoring of auxin-induced conformational changes

  • Potential approach: immunization with chemically stabilized IAA7-TIR1-auxin complexes

• Intrabodies and nanobodies:

  • Single-domain antibodies (nanobodies) against IAA7 could allow live-cell imaging of dynamic processes

  • Expressing these as intrabodies (intracellular antibodies) would enable real-time tracking of IAA7 without fixation

  • Their small size minimizes interference with IAA7 function

• Multiepitope recognition strategies:

  • Antibodies targeting multiple epitopes simultaneously could improve specificity

  • Bispecific antibodies binding both IAA7 and interaction partners could specifically detect signaling complexes

  • This approach would reduce false positives in interaction studies

• Machine learning-optimized antibodies:

  • Active learning algorithms have shown promise in improving antibody-antigen binding prediction

  • These approaches could optimize IAA7 antibody design with minimal experimental validation

  • Statistical models integrating structure prediction could guide epitope selection

• Antibody fragments with enhanced tissue penetration:

  • Fab or scFv fragments derived from IAA7 antibodies could improve tissue accessibility

  • Particularly valuable for whole-mount immunofluorescence in plant tissues

  • May reduce background by eliminating Fc-mediated binding

These innovations would address key challenges like detecting transient complexes, monitoring real-time dynamics, and improving specificity in complex biological samples.

How might IAA7 antibodies contribute to developing next-generation protein degradation technologies?

IAA7 antibodies are poised to play critical roles in advancing protein degradation technologies:

• Validation of improved degron systems:

  • The evolution from AID to AID2 systems has already demonstrated significant improvements, including reduced ligand requirements (670-fold) and elimination of leaky degradation

  • IAA7 antibodies will be essential for validating future generations of these technologies

  • Parameters to assess include: degradation kinetics, background degradation, target specificity, and reversibility

• Tissue-specific degradation monitoring:

  • As degron technologies expand to complex organisms including mice , antibodies will help validate tissue-specific degradation

  • Immunohistochemistry with IAA7 antibodies can verify system function across tissues with different accessibility

  • This application is particularly valuable given the recent success in generating mouse lines expressing OsTIR1(F74G)

• Multiplexed degradation systems:

  • Development of orthogonal degron systems will require specific antibodies for each degron

  • IAA7 antibodies will help characterize cross-talk between systems

  • Essential for applications requiring differential regulation of multiple proteins

• Quantitative degradation control:

  • IAA7 antibodies enable precise measurement of protein level reductions at different ligand concentrations

  • Critical for applications requiring partial rather than complete protein depletion

  • Supports development of dose-responsive systems with tunable degradation

• Integrated sensing and degradation circuits:

  • Future synthetic biology applications may combine sensing modules with IAA7-based degradation

  • Antibodies will validate these complex circuits and characterize their performance metrics

  • Examples include disease-responsive protein degradation systems for therapeutic applications

The rapid advancement from AID to AID2 systems has already addressed key limitations including leaky degradation and high auxin requirements . IAA7 antibodies will continue to facilitate these improvements, extending the application of degron technologies to increasingly complex biological questions.

What are the most important considerations for researchers new to using IAA7 antibodies?

Researchers beginning work with IAA7 antibodies should prioritize these key considerations:

• System-specific validation:

  • Always validate antibody specificity in your specific experimental system

  • Include appropriate positive and negative controls

  • Consider system-specific factors like expression levels, tissue type, and species differences

• Application-appropriate protocols:

  • Optimize protocols for your specific application (Western blot, IP, IF, etc.)

  • Consider the rapid degradation kinetics of IAA7 when designing time points

  • For AID/AID2 applications, carefully titrate auxin/5-Ph-IAA concentrations

• Technical challenges awareness:

  • Understand that IAA7's intrinsically disordered regions may create fixation artifacts

  • Be aware that degron tag size (mIAA7 vs. mAID) affects degradation efficiency

  • Consider that auxin binding affinity varies between wild-type and mutant/chimeric proteins

• Appropriate controls:

  • Include auxin-insensitive mutants (e.g., P87S mutation)

  • Compare different degron systems (mIAA7 vs. mAID)

  • Use genetic knockouts or knockdowns when available

• Interpreting complex results:

  • Consider how protein-protein interactions may affect epitope accessibility

  • Evaluate how experimental conditions impact IAA7 structure and function

  • Remember that IAA7 exists in a dynamic equilibrium between free and complex-bound states

By addressing these considerations, researchers new to IAA7 antibodies can design robust experiments that advance our understanding of auxin signaling and leverage the power of auxin-inducible degron technologies.

What resources and tools can support effective implementation of IAA7 antibody-based techniques?

Researchers can leverage several resources to optimize IAA7 antibody applications:

• Research reagents and materials:

  • Anti-miniIAA7 degron core sequence [AA7] monoclonal antibody is available through repositories (e.g., catalog #158027)

  • OsTIR1(F74G) expression constructs for AID2 system implementation

  • Synthetic auxin analogs like 5-Ph-IAA for controlled degradation

• Bioinformatic tools:

  • Disorder prediction algorithms to analyze IAA7 structure (as used in published studies)

  • Epitope prediction software to identify optimal antibody targets

  • Hydropathy index calculators to assess solvent exposure of potential epitopes

• Protocol repositories:

  • Optimized protocols for auxin-inducible degradation in different systems

  • Specialized immunoprecipitation methods for intrinsically disordered proteins

  • System-specific fixation and permeabilization protocols

• Data analysis tools:

  • Image analysis software for quantifying degradation kinetics

  • Statistical packages for comparing degradation efficiency across systems

  • Machine learning tools for antibody-antigen binding prediction

• Community resources:

  • Plasmid repositories containing validated constructs

  • Plant material collections with characterized iaa7 mutants

  • Method-sharing platforms with optimized protocols

• Analytical methods:

  • Binding affinity measurement approaches (as used to determine Kd values for TIR1-IAA7 interactions)

  • Protein stability assessment techniques

  • In silico modeling tools for predicting mutation effects

These resources collectively support the implementation of IAA7 antibody-based techniques across diverse research applications, from basic auxin signaling studies to advanced protein degradation technologies.